SCHEMBL2647725

SCHEMBL2647725

O=C(O)CC(O)NC(=O)c1ccc(CC(c2ccc(Cl)cc2)c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 9/20 0.75
GIPR P48546 9/20 0.75
ALOX5 P09917 1/20 0.43
KDM1A O60341 1/20 0.42
ROCK2 O75116 1/20 0.41
PRKACA P17612 1/20 0.41
RPS6KB1 P23443 1/20 0.41
IRAK1 P51617 1/20 0.41
PRKX P51817 1/20 0.41
LIMK1 P53667 1/20 0.41
PRKG2 Q13237 1/20 0.41
ROCK1 Q13464 1/20 0.41
PRKG1 Q13976 1/20 0.41
PKN2 Q16513 1/20 0.41
HIPK4 Q8NE63 1/20 0.41
AURKB Q96GD4 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
CSNK1G1 Q9HCP0 1/20 0.41
MRE11 P49959 1/20 0.40
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648419 0.86 GCGR (1.00) GCGRGIPRMEN1KMT2AMAPT
SCHEMBL2647719 0.85 GCGR (0.81) GCGRGIPRALOX5KDM1AKDM4E
SCHEMBL2647721 0.85 GCGR (0.81) GCGRGIPRALOX5KDM1AKDM4E
SCHEMBL2649467 0.77 GCGR (0.84) GCGRGIPR
SCHEMBL2654058 0.77 GCGR (0.84) GCGRGIPRKDM4EMEN1KMT2A
SCHEMBL2648554 0.76 GCGR (1.00) GCGRGIPR
SCHEMBL2648190 0.76 GCGR (1.00) GCGRGIPR
SCHEMBL2648248 0.76 GCGR (0.77) GCGRGIPRALOX5MRE11KDM4E
SCHEMBL6135179 0.76 GCGR (0.77) GCGRGIPRALOX5MRE11KDM4E
SCHEMBL2647393 0.75 GCGR (0.87) GCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256175-A1 Novel glucagon antagonists/inverse agonists LAU JESPER 2005-11-17 US disclosed
US-6881746-B2 Glucagon antagonists/inverse agonists NOVO NORDICK A/S (DK) 2005-04-19 US disclosed
EP-1519723-A1 NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2005-04-06 EP disclosed
WO-2004002480-A1 NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256175-A1 Novel glucagon antagonists/inverse agonists GLP1R, GCGR, GIPR GCGR 2/4885GIPR 3/4885ALOX5 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.